volitinib + docetaxel

Volitinib + docetaxel is a combination therapy under investigation primarily for tumors with MET amplification, such as gastric cancer. **Volitinib** (HMPL-504, also called savolitinib) is a highly selective small molecule tyrosine kinase inhibitor targeting the c-Met receptor, which is implicated in tumor growth and metastasis via the HGF/c-Met pathway. It works by inhibiting c-Met kinase activity, leading to reduced tumor cell proliferation in tumors with c-Met gene amplification or overexpression[1][4]. **Docetaxel** is a well-established chemotherapeutic agent that stabilizes microtubules and prevents cell division, showing broad efficacy in solid tumors[1]. Preclinical models and Phase I trials suggest that combining volitinib with docetaxel may yield a synergistic anti-tumor effect and improved outcomes for patients with c-Met dysregulated tumors, with additive or superior efficacy compared to monotherapy[1].

Brand names

Taxotere

Other names

volitinib + docetaxelsavolitinib + docetaxel